Protecting transplant patients from severe viral diseases
MISSION
- SpikImm is a Paris-based, clinical-stage biotech founded in 2021 by Truffle Capital in partnership with Institut Pasteur that develops monoclonal antibodies (mAbs) for the prevention of severe viral infections in transplant patients.
- Transplant patients, who receive immunosuppressive therapy to prevent rejection, are very vulnerable to viral infections and often respond poorly to vaccines.
- When exposed to viruses such as SARS-CoV-2 and BK Virus (BKV), kidney transplant patients and hematopoietic stem cell transplant patients are at high risk of developing severe forms and complications of these infections.
- To address this major unmet need, SpikImm, is currently developing a unique portfolio of long-acting human mAbs targeting different viruses. These mAbs will provide a broad, immediate and long-lasting protection for transplant patients, improving transplant outcomes, patients’ prognosis and quality of life.
TEAM
MANAGEMENT
Dr. James (Jim) Philllips
CEO
Dr. Catherine Combot-Plétan
Chief Development Officer
Pr. Karine Lacombe
Chief Medical Officer
Vincent Dagommer
Chief Financial Officer
Dr. Jérôme Tiollier
CMC expert
INVENTOR & CHIEF SCIENTIFIC OFFICER
Dr. Hugo Mouquet
BOARD OF DIRECTORS
Dr. Philippe Pouletty
Chairman